Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies
  • Posted: 03/21/2006
  • Updated: 04/26/2007

Combination Therapy for Peritoneal Carcinomatosis

Name of the Trial

Phase III Randomized Study of Operative Debulking and Systemic Chemotherapy with or without Intra- and Peri-Operative Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Low-Grade Gastrointestinal Adenocarcinoma (NCI-03-C-0085). See the protocol summary.

Principal Investigator

Dr. James Pingpank
Dr. James Pingpank
Principal Investigator

 Dr. James Pingpank, NCI Center for Cancer Research.

Why This Trial Is Important

Peritoneal carcinomatosis is a rare type of metastatic cancer in which tumors form throughout the peritoneum, the membrane that lines the abdominal cavity. Several types of cancer may cause peritoneal carcinomatosis, but it is often associated with gastrointestinal cancers. Without aggressive treatment, peritoneal carcinomatosis is almost always fatal.

In this clinical trial, patients with peritoneal carcinomatosis from low-grade gastrointestinal cancers will be treated with surgery to remove all visible tumors (operative debulking). During surgery, half of the patients will also be treated with hyperthermic chemotherapy administered directly into the peritoneal cavity (continuous hyperthermic peritoneal perfusion). These patients will receive additional intraperitoneal chemotherapy within 2 weeks after surgery. All patients will receive systemic chemotherapy 4 to 6 weeks after surgery.

Researchers hope to determine whether adding continuous hyperthermic peritoneal perfusion to operative debulking will help delay the progression of peritoneal carcinomatosis and result in longer survival.

"Many patients with low-grade gastrointestinal carcinomas develop peritoneal carcinomatosis rather than distant metastases," said Dr. Pingpank. "We know the most important aspect of treatment for these patients is complete resection of the tumors. What we hope to determine is whether adding the intraperitoneal perfusion will provide an added benefit that would justify the potential toxicity of the procedure."

Contact Information

This clinical trial is no longer accepting new patients. To locate other clinical trials for gastrointestinal cancers, search the NCI's database of clinical trials or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The toll-free call is completely confidential.